Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00928551 | Comparative Formulation Study of Vabicaserin | PHASE1 | COMPLETED | 15 | — | — | Jun 1, 2009 | Sep 1, 2009 | Sep 11, 2009 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| vabicaserin | DRUG | - |
Inclusion Criteria: * Sexually active men must agree to use a medically acceptable form of contraception during the study and continue it for 12 weeks after investigational product administration. * Nonsmoker or smoker of fewer than 10 cigarettes per day as determined by history. Must be able to ab...